Advair
Product Images NDC 21695-196

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Advair (NDC 21695-196). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1. Cumulative Incidence Of Asthma-related Deaths In The 28-week Salmeterol Multi-center Asthma Research Trial (smart), By Duration Of Treatment (9e0bdea8 Df9b 4873 B24b 919cebff5edd 01)

This image contains three cumulative incidence line graphs showing asthma-related death over treatment duration in days for ADVAIR DISKUS. The three graphs compare outcomes for all subjects, Caucasian subjects, and African American subjects. Each graph includes separate lines for Salmeterol and placebo groups, with corresponding numbers at risk at various time points.*

FDA Label Image

Fluticasone Propionate Chemical Structure (9e0bdea8 Df9b 4873 B24b 919cebff5edd 02)

Chemical structure of the active ingredient in ADVAIR DISKUS. The diagram depicts the molecular formula with labeled atoms and bonds representing the compound's chemical arrangement.*

FDA Label Image

Salmeterol Xinafoate Chemical Structure (9e0bdea8 Df9b 4873 B24b 919cebff5edd 03)

Chemical structure diagram showing the molecular structures of the active ingredients in ADVAIR DISKUS. The image depicts two distinct chemical compounds represented by their skeletal formulas with hydroxyl, carboxyl, and amine functional groups visible.*

FDA Label Image

Figure 2. Mean Percent Change From Baseline In Fev1 In Patients With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (study 1) (9e0bdea8 Df9b 4873 B24b 919cebff5edd 04)

Line graph depicting % change in FEV1 over 12 weeks and at endpoint for ADVAIR DISKUS 100/50 twice daily, fluticasone propionate 100 mcg twice daily, salmeterol 50 mcg twice daily, and placebo. The graph compares lung function changes among these treatments over time.*

FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Patients With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (study 1) (9e0bdea8 Df9b 4873 B24b 919cebff5edd 05)

A line graph comparing the percentage change in FEV1 over 12 hours for four groups: ADVAIR DISKUS 100/50 twice daily, Salmeterol 50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, and Placebo. The x-axis represents time in hours, and the y-axis shows percentage change in FEV1 from baseline.*

FDA Label Image

Figure 4. Percent Change In Serial 12-hour Fev1 In Patients With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (study 1) (9e0bdea8 Df9b 4873 B24b 919cebff5edd 06)

A line graph showing the percentage change in FEV1 relative to Day 1 baseline over a 12-hour period at Week 12 baseline. The graph compares ADVAIR DISKUS 100/50 twice daily with salmeterol 50 mcg twice daily, fluticasone propionate 100 mcg twice daily, and placebo, indicated by different symbols and lines.*

FDA Label Image

Figure 5. Predose Fev1: Mean Percent Change From Baseline In Patients With Chronic Obstructive Pulmonary Disease (9e0bdea8 Df9b 4873 B24b 919cebff5edd 07)

A line graph showing the percent change in FEV1 over 24 weeks for ADVAIR DISKUS 250/50, Salmeterol 50 mcg, and placebo groups. The x-axis represents weeks and the y-axis represents percent change in FEV1. Data points show higher improvement with ADVAIR DISKUS compared to Salmeterol and placebo. Sample sizes (N) for each group at various points are also included below the graph.*

FDA Label Image

Figure 6. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Patients With Chronic Obstructive Pulmonary Disease (9e0bdea8 Df9b 4873 B24b 919cebff5edd 08)

Line graph showing the percent change in FEV1 over 24 weeks for ADVAIR DISKUS 250/50, Fluticasone propionate 250 mcg, and placebo. The graph includes baseline FEV1 values and participant numbers at various time points, illustrating the improvement in lung function with ADVAIR DISKUS compared to the other groups over time.*

FDA Label Image

Diskus Parts (9e0bdea8 Df9b 4873 B24b 919cebff5edd 09)

Illustration of ADVAIR DISKUS inhaler labeled with its key parts including mouthpiece, lever, dose indicator, thumbgrip, and outer case. The central label shows the strength of 100/50 with fluticasone propionate and salmeterol inhalation powder.*

FDA Label Image

Figure 1 (9e0bdea8 Df9b 4873 B24b 919cebff5edd 10)

An illustration showing a portion of the ADVAIR DISKUS inhalation device. The image features details of the device's curved outer edge and part of the white circular label with some text, highlighting design elements of the labeler Rebel Distributors Corp. product.*

FDA Label Image

Figure 2 (9e0bdea8 Df9b 4873 B24b 919cebff5edd 11)

An instructional illustration showing a hand holding an ADVAIR DISKUS inhaler. The image includes an arrow indicating a twisting motion on the device, likely to prepare it for use or release a dose.*

FDA Label Image

Figure 3 (9e0bdea8 Df9b 4873 B24b 919cebff5edd 12)

An instructional illustration showing a hand holding an ADVAIR DISKUS inhaler. The image depicts the proper way to hold and operate the inhaler device by twisting the base to prepare a dose for inhalation.*

FDA Label Image

Figure 4 (9e0bdea8 Df9b 4873 B24b 919cebff5edd 13)

An illustration depicting a person holding an inhaler device near their mouth, demonstrating how to use the inhaler. The image does not specify the product brand or dosage.*

FDA Label Image

Figure 5 (9e0bdea8 Df9b 4873 B24b 919cebff5edd 14)

Illustration showing a person using an ADVAIR DISKUS inhaler device. The individual is holding the Diskus near their mouth, demonstrating how to inhale the medication.*

FDA Label Image

Figure 6 (9e0bdea8 Df9b 4873 B24b 919cebff5edd 15)

Illustration showing a person holding an ADVAIR DISKUS inhaler device with one hand gripping the bottom and the other hand ready to rotate the lever, demonstrating how to prepare the inhaler for use as part of the inhalation process.*

FDA Label Image

Advair 250/50mcg (9e0bdea8 Df9b 4873 B24b 919cebff5edd 16)

Label for Advair Diskus 250/50 mcg powder inhaler by Rebel Distributors Corp. The label includes dosage strength, product ID RA019601, and mentions manufacturer Glaxo Operations UK, Ltd. It is distributed by Physician Partner in Thousand Oaks, CA. The label features storage instructions and emphasizes prescription-only status with lot and expiration placeholders.*

FDA Label Image

Advair 500/50mcg (9e0bdea8 Df9b 4873 B24b 919cebff5edd 17)

ADVAIR DISKUS 500/50mcg powder inhaler label showing dosage strength and drug description. The label includes details about each blister containing 500mcg fluticasone propionate and 72.5mcg salmeterol xinafoate equivalent to 50mcg salmeterol base. Label shows NDC 21695-197-01, Product ID RA019701, manufactured by Glaxo Operations UK Ltd., and distributed by Physician Partner, Thousand Oaks, CA. Storage instructions and safety warnings are printed on a red band at the bottom.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.